DSMB Recommends UniQure To Continue Huntington's Gene Therapy Trial Unchanged

• The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial evaluating UniQure NV's (NASDAQ: QURE) AMT-130 for Huntington's disease.

• The DSMB recommended continued dosing in the study. UniQure will now begin to enroll patients in the higher-dose cohort of the trial.

• To date, six patients have been treated with AMT-130, and four patients received imitation surgery.

• The company remains on track to initiate clinical development of AMT-130 in Europe in the second half of 2021 and share initial imaging and biomarker data from the U.S. clinical trial before the end of 2021.

• Price Action: QURE shares are up 2.35% at $34.01 on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Acutus Medical Receives Green Signal From FDA To Start AcQBlate Atrial Fibrillation Trial

• Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.